AG01
Based on 1 Customer Validation
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers.
For research use only. We do not sell to patients.
- Purity: 95.10%
- Molecular Weight:147.60 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
|
ERK1 |
ERK2 |
MMP-2 |
Axl |
HIF-1α |
AG01 (0-300 µg/mL, 48-72 h) inhibits cells proliferation, reduces Ki67-positive nuclei quantification in MDA-MB-231, HS578-T cells[1].
AG01 (0-100 µg/mL, 5 h) inhibits cells migration and invasion in MDA-MB-231, HS578-T cells[1].
AG01 (100 µg/mL, 24-72 h) decreases the phosphorylation status of AKt, Src, Erk1/2 in MDA-MB-231, HS578-T cells[1].
AG01 (100 µg/mL, 24-72 h) decreases the proteins expression of Axl, c-MET, ICAM-1, MMP-2, SNAIL, HIF-1α, VEGF, endogenous progranulin, SPARC, cell adhesion and migratory protein-fbronectin in MDA-MB-231, HS578-T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231, HS578-T cells
-
Concentration:0, 25, 50, 100, 200, 300 µg/mL
-
Incubation Time:48, 72 h
-
Result:Inhibited cells proliferation, resulted in a dose-dependent inhibition of MDA-MB-231 and HS578-T cells proliferation by 44% and 51% at 300 µg/mL compared with control.
-
Cell Line:MDA-MB-231, HS578-T cells
-
Concentration:25, 50, 100 µg/mL
-
Incubation Time:5 h
-
Result:Inhibited cells migration in a dose-dependent, with the highest reduction of 78.2%, 77.5% at 100 µg/mL for MDA-MB-231, HS578-T cells.
-
Cell Line:MDA-MB-231, HS578-T cells
-
Concentration:100 µg/mL
-
Incubation Time:24, 48, 72 h
-
Result:Decreased the phosphorylation status of Akt (14.8%), Src (23.6%), and Erk1/2 (20.3%) at 24 h and decreased phosphorylation of Akt (63%), Src (55.4%), and Erk1/2 (55.2%) at 72 h compared to control, decreased the ratio of phosphorylated protein to its total corresponding protein expression for Akt (71.9%), Src (49.8%), and Erk1/2 (62%) at 72 h in MDA-MB-231 cells.
Decreased the phosphorylation status of Akt (44.5%), Src (31.5%), and ERK1/2 (35.5%) at 24 h while decreased FAK phosphorylation (44.5%) at 48 h, decreased the ratio of phosphorylated protein to its total corresponding protein expression for p-Src/Src (44.3%), p-Akt/Akt (47.3%), and p-ERK1/2/ERK (46%) at 48 h in HS578-T cells.
Reduced c-MET expression of 59.7%.
Reduced SNAIL expression of 23.3% and 89%, ICAM-1 of 93.8% and 33.8%, AXL of 13.2% and 33.4% in MDA-MB-231 and HS578-T cells, respectively, reduced endogenous progranulin level in time-dependent reduction with MDA-MB-231 showing 37.7% reduction by 72 h and HS578-T showing almost a 100% reduction by 48 h.
Reduced cell adhesion and migratory protein-fbronectin in time-dependent decrease of 25.4% at 72 h as compared to its control lysate in MDA-MB-231 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDA-MB-231 (1.5x106) xenograft nude mice (6-8-week-old, female) model[1]
-
Dosage:10 mg/kg
-
Administration:i.p., twice weekly, 40 days
-
Result:Reduced Vt/V0 ratio and tumor weights by 50% compared to control human IgG treated group, reduced Ki67 expression in tumor sections by 52.5% compared to control groups, showed a 50% reduction of the mitotic index compared to control and 65% reduction of relative microvessel numbers compared to control HuIgG-treated animals.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
NP_002078.1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Molecular Weight 147.60 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)